Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab re-treatment in SLE
NCT00383513Phase 2Completed
- Sponsor
- UCB
- Start
- Jun 2006
- Primary completion
- Jan 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoints: Number of subjects reporting at least 1 serious adverse event at 6 years and Number of subjects prematurely discontinuing due to a treatment emergent adverse event at 6 years. Started Jun 2006; status: completed.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00383513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383513.